23 Mar 2017 For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624. Email: renate.birkeli@targovax.com

Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to

Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors; 8.3.2021, 07:00 · Oslo Børs TRVX: Targovax to present and attend at upcoming investor and scientific conferences; 8.3.2021, 07:00 · Cision Targovax to present and attend at upcoming investor and scientific conferences Renate Birkeli, Investor Relations. Phone: +47 922 61 624. Email: renate.birkeli@targovax.com Media and IR enquires: Jan Petter Stiff – Crux Advisers (Norway) Phone: +47 995 13 891. Email: stiff@crux.no Julia Phillips/Simon Conway – FTI Consulting (International) Phone: +44 20 3727 1000.

The documents are also available at the Company’s website, www.targovax.com. 1904 TRVX Annual report. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE FIRST QUARTER 2018 2021-02-15 · Targovax receives Fast-Track designation for ONCOS-102 - The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma Targovax AS develops active immunotherapy in the form of cancer vaccines. The lead candidate TG01 is currently in a phase I/II clinical trial in resectable pancreatic cancer.

Regulatory news and announcemnets. Learn more. Contact.

During the silent period, Investor Relations does not arrange any meetings with the press, media, investors, analysts or other capital market players. Normally this period occurs from the fifth banking day of the new quarter and until the interim report has been published.

Targovax has a diversified immune activator portfolio and aims to become a leader in this area. Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer.

Targovax expresses the company’s gratitude for the excellent work Mr. Vink has done as Chairman of the Board over the past three years. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway)

07.21.2021. 08:30 AM ET. Second Quarter 2021 Earnings.

INVESTOR RELATIONS Välkommen till NOTEs Investor Relations! HENRIK NYGREN. Chief Financial Officer Tel: 070-977 06 86 E-post: Henrik.Nygren@note-ems.com. Kommande nyheter. Filter by year: Många nya jobb väntas hos NOTE i Torsby i samband med utbyggnationen av fabriken.
Observer bias

The ironSource story. ironSource is a leading business platform that enables mobile content creators to prosper within the app economy. OSLO, Norway, Oct. 28, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB).

touché !!! http://www.cassandraoil.com/sv/Investor-Relations/Aktien/Insiderlista/. 9 helmikuu 2015 Tykkää (1) Investors & Media Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area.
Molekylar formel

maria clara tonini
orkanen malmö restaurang
fransk modehus
varför är kvicksilver farligt för miljön
vad är marknadsföring_

On 17 February 2021, the Board of Directors of Targovax ASA approved the Company's Kim Sutton Golodetz - LHA Investor Relations (US)

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. 2021-04-06 · Investor: Number of Shares % of top 20 % of total: Type: Country: HealthCap: 12 471 675: 29,41%: 14,41%: NOM: SWE: RADFORSK INVESTERINGSSTIFTELSE: 4 427 255: 10,44%: 5,11%: COMP: NOR: FJARDE AP-FONDEN: 4 000 000: 9,43%: 4,62%: COMP: SWE: THORENDAHL INVEST AS: 1 750 000: 4,13%: 2,02%: COMP: NOR: VERDIPAPIRFONDET NORDEA KAPITAL: 1 748 448: 4,12%: 2,02%: COMP: NOR: VERDIPAPIRFONDET NORDEA AVKASTNING: 1 649 274: 3,89%: 1,91% 2021-03-18 · Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Targovax Annual Report 2019. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com.

The Investor Relations website contains information about Targa Resources Corp.'s business for stockholders, potential investors, and financial analysts.

SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer. Vissa menar att när ett mindre intervall (50) skär ett högre (200) så … Levi Strauss & Co. is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's ®, Dockers®, Signature by Levi Strauss & Co.™, and Denizen ® from Levi’s ® brands. Its products are sold in more than 110 countries worldwide through a The Ericsson Investor Relations, website contains information about Ericsson for current stockholders, potential investors and institutional analysts, regarding stock information, earnings reports, SEC filings, upcoming events, investor news and more.

Last … Investor Relations Today, IBM has laid the foundation for a new era of technology and business. See the Q4 2020 Earnings Announcement Explore the 2020 Annual Report Earnings & financials. Financial reporting.